• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of versatile antiviral medicines using advanced decoy particles for topical mucosal formulations

Research Project

Project/Area Number 18K06753
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionGifu Pharmaceutical University

Principal Investigator

Tahara Kohei  岐阜薬科大学, 薬学部, 教授 (30454325)

Co-Investigator(Kenkyū-buntansha) 井上 直樹  岐阜薬科大学, 薬学部, 教授 (90183186)
竹内 洋文  岐阜薬科大学, 薬学部, 特任教授 (50171616)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywordsリポソーム / ナノ粒子 / ウイルス
Outline of Final Research Achievements

We have found that liposomes and polymeric nanoparticles can potently inhibit viral infection of host cells. This phenomenon suggested that the nanoparticles themselves act as decoys for the cells and inhibit viral infection, leading to innovative drug therapeutics for infectious diseases. However, the inhibition mechanism of viral infection was unclear. In this study, we demonstrated that biocompatible nanoparticles such as cationic liposomes exhibited antiviral effects in vitro and in vivo using herpes and influenza viruses. In addition, it was shown that the nanoparticles adsorbed on the virus particles and caused particle aggregation, thereby exhibiting antiviral effects.

Academic Significance and Societal Importance of the Research Achievements

生体適合性微粒子の薬剤応用は、微粒子へ薬物を含有させ、薬物の運び屋として利用する場合がほとんどである。薬剤を搭載しない微粒子でウイルス感染を抑制しようとする本研究のコンセプトはこれまでにほとんど報告がなく、抗ウイルス微粒子の可能性を証明すれば創薬の新たなパラダイムとなる可能性がある。ウイルスの分子生物学的な形質の多様性は著しく高い。そのため、個々ウイルスの治療薬が必要となる。抗ウイルス微粒子の場合、感染の初期段階である細胞膜吸着を阻害するため、広域なスペクトルを有する治療薬となる。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (4 results)

All 2021 2020 2018

All Journal Article (4 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 3 results,  Open Access: 1 results)

  • [Journal Article] Oral mucus-penetrating PEGylated liposomes to improve drug absorption: Differences in the interaction mechanisms of a mucoadhesive liposome2021

    • Author(s)
      Yamazoe Eriko、Fang Jia-You、Tahara Kohei
    • Journal Title

      International Journal of Pharmaceutics

      Volume: 593 Pages: 120148-120148

    • DOI

      10.1016/j.ijpharm.2020.120148

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Pharmaceutical formulation and manufacturing using particle/powder technology for personalized medicines2020

    • Author(s)
      Tahara Kohei
    • Journal Title

      Advanced Powder Technology

      Volume: 31 Issue: 1 Pages: 387-392

    • DOI

      10.1016/j.apt.2019.10.031

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Effects of cationic liposomes with stearylamine against virus infection2018

    • Author(s)
      Tahara Kohei、Kobayashi Manami、Yoshida Satoko、Onodera Risako、Inoue Naoki、Takeuchi Hirofumi
    • Journal Title

      International Journal of Pharmaceutics

      Volume: 543 Issue: 1-2 Pages: 311-317

    • DOI

      10.1016/j.ijpharm.2018.04.001

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] 生体適合性ナノ粒子を利用した非侵襲的・局所 DDS 製剤の開発2018

    • Author(s)
      田原耕平、竹内洋文
    • Journal Title

      医薬品医療機器レギュラトリーサイエンス

      Volume: 48 Pages: 735-741

    • NAID

      40021400860

    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi